Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vonacor
- Development stage
- Unknown
- Lead developer
- Optimal Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vonacor is a dietary supplement and medical food designed for the dietary management of osteoarthritis and joint pain. Developed by Optimal Laboratories, a company founded by sports medicine physician Dr. Vad and pharmacist Steven Gelwan, the product features a specialized formulation of curcumin known as MicroActive Curcumin. This turmeric root extract is standardized to 25% curcuminoids and combined with turmeric oil in a 500mg capsule. Vonacor utilizes patented MicroActive microtechnology to enhance the bioavailability of curcumin, achieving a 9.7-fold increase in absorption compared to standard curcumin formulations. Mechanistically, Vonacor works by regulating the body's inflammatory response, specifically by blocking Interleukin-1 (IL-1) and modulating various inflammatory enzymes and cytokines to support joint health and mobility. The product is marketed as a vegan, non-GMO, and gluten-free option available through physicians' offices, pharmacies, and direct-to-consumer channels.
- Brand names
- Vonacor
02
Targets
MRP5 (ATP-binding cassette sub-family C member 5)GSTA1 (Glutathione S-transferase A1)GSTM1 (Glutathione S-transferase Mu 1)GSTP1 (Glutathione S-transferase P)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))NF-κBIL1A (Interleukin 1 alpha)
Beyond the preview
Go deeper on Vonacor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vonacor.